BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - European stocks turned in a mixed performance on Tuesday, reacting to the latest batch of earnings announcements and economic data from the region.The undertone
OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE
® in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
On May 17, 2021, JT notified OPKO of its decision to terminate the exclusive agreement with OPKO’s subsidiary, EirGen Pharma, Ltd., for the development and commercialization of RAYALDEE
® in Japan based on a comprehensive review of its development pipeline.
Concurrently with the termination of JT’s rights, EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE
® in Japan to VFMCRP by including Japan into the existing exclusive agreement between the two companies, executed on May 9, 2016, for the development and commercialization of RAYALDEE
ACB, PPDA mum on blacklisting of corruption-laden Fresenius Medical Care nyasatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nyasatimes.com Daily Mail and Mail on Sunday newspapers.
Deals of the day-Mergers and acquisitions Reuters 2 hrs ago
Popular Searches
May 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1445 GMT on Friday: Travis Perkins, Britain s biggest seller of building materials, will return cash to shareholders after selling its plumbing and heating business to an affiliate of investment firm H.I.G. Capital for 325 million pounds ($461 million). Italian payments group Nexi is in talks with Alpha Bank to take a stake in the Greek bank s retailers payment business, four sources close to the matter said. Biffa said it would buy the collections business and certain recycling assets from Viridor Waste Management Ltd for 126 million pounds ($178.87 million), as the waste-management specialist solidifies its position in the UK.
The growth of this market is driven by increasing investments, funds, and grants for research on heart failure treatment; rising prevalence of cardiovascular diseases; long waiting periods for heart transplants; favorable reimbursements for heart pump devices; and increasing obesity.
Ventricular assist devices are expected to hold the largest share of the heart pump device market, by product in 2021.
Based on products, the heart pump devices market is segmented into ventricular assist devices, intra- aortic balloon pumps, and total artificial hearts. Ventricular assist devices are the largest and fastest-growing segment in this market. Growth in this segment can primarily be attributed to technological advancements, the shortage of organ donors, and the increasing prevalence of heart failure globally.